Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. 

From the week of February 09th, we are planning to work on 17 projects, including: 

Reimbursement 

  1. Delivering reimbursement analysis for a medical device used in gastrointestinal surgery in Switzerland  

  2. Delivering reimbursement analysis for novel technology in organ transplantation in France 

  3. Working on market access strategy for minimally invasive technology in the urology area in eight European countries 

  4. Working on market access strategy for invasive diagnostic imaging technology in the cardiovascular area in England, France, and Germany 

  5. Working on reimbursement analysis for surgical treatment in orthopedic area in Germany and Switzerland 

  6. Working on reimbursement analysis for extracorporeal treatment in ten European countries 

  7. Working on reimbursement analysis diagnostic and therapeutic procedure in cardiovascular area in England, France, Germany, and Italy 

  8. Initiating work on reimbursement analysis for an in-vitro diagnostic test in hematology area in England, France, Germany, and Italy 

  9. Initiating work on reimbursement analysis for minimally invasive technology in neurology area in Denmark, Finland, Norway and Sweden 

  10. Initiating work on reimbursement analysis for an in-vitro diagnostic test in oncology area in France, Germany, Italy, and Spain 

 

HEOR 

  1. Delivering a clinical value dossier for treatment technology in the dermatology area 

  2. Working on the development of a health economic model for in-vitro diagnostic tests in neurology disease areas in England, France, Germany, Italy, and Spain  

  3. Working on the adaptation of a health economic model for an imaging diagnostic system in different European and Middle Eastern countries 

  4. Working on the validation of a health economic model in the cardiology area 

  5. Working on a value dossier update for an in-vitro diagnostic test in the oncology area 

  6. Working on two systematic literature reviews for a minimally invasive technology in the neurology area 

  7. Working on a systematic literature review and meta-analysis for an in vitro diagnostic test 

Let us know if you need any market access or HEOR support for your medical technology in Europe